Cargando…

The impact of RAS mutation on the treatment strategy of colorectal cancer

Kirsten rat sarcoma (KRAS) is the most frequently mutated oncogene in colorectal cancer, being present in 30% of patients with localized disease and in almost half of the patients that develop metastatic disease. While the development of chemotherapy doublets and targeted therapy have improved survi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirvu, Edvina Elena, Severin, Emilia, Niţă, Irina, Toma, Ştefania Andreea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iuliu Hatieganu University of Medicine and Pharmacy 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924809/ https://www.ncbi.nlm.nih.gov/pubmed/36818322 http://dx.doi.org/10.15386/mpr-2408

Ejemplares similares

Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania
por: Pîrvu, Edvina Elena, et al.
Publicado: (2023)

The importance of androgen receptors in breast cancer
por: Niţă, Irina, et al.
Publicado: (2021)

Histological Aspects and Quantitative Assessment of Ki67 as Prognostic Factors in Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study
por: Niță, Irina, et al.
Publicado: (2020)

Correlation between Androgen Receptor Expression and Immunohistochemistry Type as Prognostic Factors in a Cohort of Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study
por: Niță, Irina, et al.
Publicado: (2021)

Level of education, background and clinical stage as prognostic factors according to RMST function in patients with early and locally advanced breast cancer: a single institution experience from Romania
por: Niţă, Irina, et al.
Publicado: (2022)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
por: Rossi, Luigi, et al.
Publicado: (2013)

Therapeutic impact of determination of RAS mutations in the plasma of patient with colorectal cancer
por: Macedo, F, et al.
Publicado: (2022)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
por: Giordano, Guido, et al.
Publicado: (2021)

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer
por: Dolatkhah, Roya, et al.
Publicado: (2021)

Surgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation Status
por: Wei, Steven H., et al.
Publicado: (2015)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

Fast simultaneous detection of K-RAS mutations in colorectal cancer
por: Chang, Ya-Sian, et al.
Publicado: (2009)

Spectrum of K ras mutations in Pakistani colorectal cancer patients
por: Murtaza, B.N., et al.
Publicado: (2013)

Comparison of K-ras mutations in lung, colorectal and gastric cancer
por: PENG, NANQIU, et al.
Publicado: (2014)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
por: Mattox, Tyler E., et al.
Publicado: (2019)

Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers
por: Ionescu, Adriana, et al.
Publicado: (2022)

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases
por: Rhaiem, Rami, et al.
Publicado: (2022)

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
por: Andreyev, H J N, et al.
Publicado: (2001)

High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer
por: Jeantet, Marion, et al.
Publicado: (2016)

The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system.
por: Fox, J. C., et al.
Publicado: (1998)

Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems
por: Irimia, Teodora, et al.
Publicado: (2018)

Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
por: Wang, Xiaojie, et al.
Publicado: (2021)

RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015)

K-ras Mutation in Colorectal Cancer, A Report from Southern Iran
por: Omidifar, Navid, et al.
Publicado: (2015)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer
por: Zhu, Liuying, et al.
Publicado: (2020)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

RAS‐targeted cancer therapy: Advances in drugging specific mutations
por: Liu, Cen, et al.
Publicado: (2023)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Emerging strategies to target RAS signaling in human cancer therapy
por: Chen, Kun, et al.
Publicado: (2021)

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
por: Valladares-Ayerbes, Manuel, et al.
Publicado: (2022)

Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
por: Lastraioli, Elena, et al.
Publicado: (2023)

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
por: Miller, Mark Steven, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rhnd617r0jpr8emgfeb78oa9am